An Accessorised Prefilled Syringe to an Autoinjector Pharmacokinetic Bridging Study of Tozorakimab
A Multiple Centre, Randomised, Open-label, Parallel Group, Phase I Pharmacokinetic Comparability Study of Tozorakimab Administered Using an Accessorised Prefilled Syringe (APFS) or an Autoinjector (AI) in Healthy Volunteers
Sponsor: AstraZeneca
This PHASE1 trial investigates Healthy Participants and is currently completed. AstraZeneca leads this study, which shows 8 recorded versions since 2025 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
8 versions recorded-
Jan 2026 — Present [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Dec 2025 — Jan 2026 [monthly]
Active Not Recruiting PHASE1
-
Oct 2025 — Dec 2025 [monthly]
Active Not Recruiting PHASE1
-
Sep 2025 — Oct 2025 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Aug 2025 — Sep 2025 [monthly]
Recruiting PHASE1
▶ Show 3 earlier versions
-
Jul 2025 — Aug 2025 [monthly]
Recruiting PHASE1
-
Jun 2025 — Jul 2025 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
May 2025 — Jun 2025 [monthly]
Not Yet Recruiting PHASE1
First recorded
Apr 2025
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
- Parexel
For direct contact, visit the study record on ClinicalTrials.gov .